News Center

Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics

11月 9, 2020 | 未分类
SAN DIEGO, November 9, 2020 – Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced today the successful closing of an oversubscribed...

Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics

1月 13, 2020 | 未分类
Sino Biopharma receives exclusive rights to develop and commercialize two Ambrx enabled drug products in China Ambrx receives upfront payment plus undisclosed milestone payments and royalties. SAN DIEGO, USA and BEIJING,...

A Phase 1 Study of ARX788, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Metastatic HER2-Positive Breast Cancer

12月 11, 2019 | 未分类
San Antonio Breast Cancer Symposium 2019 - ARX788 SABCS poster...

Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx’s Antibody Drug Conjugates

10月 22, 2019 | 未分类
SAN DIEGO and SHANGHAI, October 22, 2019 /PRNewswire/ -- Ambrx and NovoCodex Biopharmaceuticals Ltd., (NovoCodex), a majority owned company of Zhejiang Medicine Co Ltd., today announced that they have formed...

Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative

7月 16, 2019 | 未分类
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin...